Publications
- Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group2021 | Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Frontline treatment with the combination obinutuzumab +/- chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group2020 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Single-agent ibrutinib in RESONATE-2TM and RESONATETM versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia2019 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Small Molecules in the Treatment of Chronic Lymphocytic Leukemia in 2015 and in the Near Future2015 | First Faculty of Medicine
- New drugs for the treatment of chronic lymphocytic leukemia2015 | First Faculty of Medicine
- Idelalisib in the treatment of chronic lymphocytic leukaemia2015 | First Faculty of Medicine
- Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients2015 | Faculty of Medicine in Hradec Králové
- Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients2015 | Publication without faculty affiliation
- Guidelines for alemtuzumab treatment in chronic lymphocytic leukemia (CLL)2012 | First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)2023 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
Loading network view...